Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00520208 · ClinicalTrials.gov registry record · Phase 2
Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
A Phase 2 study of Acute Promyelocytic Leukemia, sponsored by CytRx.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 2
- Study locations
NCT00520208: Completed Phase 2 study of Acute Promyelocytic Leukemia, sponsored by CytRx.
NCT00520208 is a Phase 2 study of Acute Promyelocytic Leukemia that has completed, run by CytRx. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00520208, a Phase 2 study of Acute Promyelocytic Leukemia, has completed, sponsored by CytRx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a Phase II, open-label, non-randomized study to evaluate the safety, efficacy, and pharmacokinetics of tamibarotene in adult patients with relapsed or refractory acute promyelocytic leukemia (APL) following treatment with all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO). Patients must have received and failed therapy with ATRA and ATO. Treatment may have been administered either as combination therapy or sequentially as single agents. Patients who are intolerant to either drug are eligible for this study.
Conditions Studied
Interventions
- DRUG Tamibarotene
Study Locations (2)
Illinois
- Northwestern University - Chicago
Texas
- UT MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2007-09 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
What the finished NCT00520208 record still lists
NCT00520208 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Acute Promyelocytic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Tamibarotene is the first listed.
NCT00520208 reports a single indexed study location in Illinois, Texas.
Frequently Asked Questions
What is clinical trial NCT00520208 about?
NCT00520208 is a clinical study titled "Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL". This is a Phase II, open-label, non-randomized study to evaluate the safety, efficacy, and pharmacokinetics of tamibarotene in adult patients with relapsed or refractory acute promyelocytic leukemia (APL) following treatment with all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO). Patients mu...
What is the current status of trial NCT00520208?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2007-09. Estimated completion is 2013-01.
What conditions does trial NCT00520208 study?
This clinical trial studies the following conditions: Acute Promyelocytic Leukemia.
What interventions are being tested in trial NCT00520208?
The interventions under investigation include: Tamibarotene (DRUG).
Who is sponsoring clinical trial NCT00520208?
This trial is sponsored by CytRx, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00520208 being conducted?
This trial has 2 study locations across Illinois, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Promyelocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00520208's enrollment target sits among peer trials
15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia